WASHINGTON, May 22, 2019 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced the
results of the Phase II study of tradipitant in gastroparesis were
presented at Digestive Disease Week® (DDW) 2019 in
San Diego, CA.
For more information on DDW 2019, please refer to
https://ddw.org/home.
About Vanda
Vanda is a global biopharmaceutical company focused on the
development and commercialization of innovative therapies to
address high unmet medical needs and improve the lives of
patients. For more on Vanda Pharmaceuticals Inc., please
visit www.vandapharma.com.
Investor Contact:
Jim
Kelly
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com
Media Contacts:
AJ Jones II
Burson Cohn & Wolfe (BCW)
1110 Vermont Avenue, NW, Suite 1200
Washington, D.C. 20005
202-530-0400
pr@vandapharma.com
Elizabeth Van Every
Burson Cohn & Wolfe (BCW)
230 Park Avenue South
New York, NY 10003
212-614-3881
pr@vandapharma.com
View original
content:http://www.prnewswire.com/news-releases/tradipitant-in-the-treatment-of-gastroparesis-vanda-presents-clinical-trial-results-at-ddw-2019-300855295.html
SOURCE Vanda Pharmaceuticals Inc.